CEACAM1 and colorectal carcinoma: Research has shown that F. nucleatum can bind and activate the human inhibitory receptor CEACAM1 to inhibit the activities of T cells and NK cells, suggesting that CEACAM1 inhibitors could be used to treat Fusobacterium-colonized CRC (Gur et al., 2019).